Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a gm-csf secreting pancreatic tumor vaccine

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Schueneman, Aaron J ^a   Sugar, Elizabeth A ^a,b   Uram, Jennifer ^a   Bigelow, Elaine ^a   Herman, Joseph M ^a   Edil, Barish H ^a,c   Jaffee, Elizabeth M ^a   Zheng, Lei ^a   Laheru, Daniel A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; ANTINEOPLASTIC ANTIMETABOLITE; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; VERY ELDERLY; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; SECRETION (PROCESS); SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CANCER VACCINES; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84892792945     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3262-5     Document Type: Article

References (30)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
3. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
4. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
5. Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Bianconi M, Cascinu S. Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol. 2008;67:27-38.
6. Picozzi VJ, Pisters PW, Vickers SM, Strasberg SM. Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg. 2008;12:657-61.
7. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145-56.
8. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455-63.
9. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factorsecreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328-35.
10. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(?) T cell responses provide evidence of in vivo crosspriming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200:297-306.
11. Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17:5473-80.
12. Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;36:617-22.
13. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:425-8.
14. Garcea G, Ladwa N, Neal CP, et al. Preoperative neutrophil-tolymphocyte ratio (NLR) is associated with a reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011;35:868-72.
15. Fabris N, Piantanelli L. Differential effect of pancreatectomy on humoral and cell-mediated immune responses. Clin Exp Immunol. 1977;28:315-25.
16. Takahashi K, Toyokawa H, Takai S, et al. Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother. 2006;55:775-84.
17. Terando A, Mule JJ. On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother. 2003;52:680-5.
18. Emens LA, Machiels JP, Reilly RT, Jaffee EM. Chemotherapy: friend or foe to cancer vaccines?CurrOpinMol Ther. 2001;3:77-84.
19. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-26.
20. Lissoni P, Brivio F, Fumagalli L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers. 2004;19:135-40.
21. De Angulo G, Hernandez M, Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol. 2007;29:48-52.
22. Clark EJ, Connor S, Taylor MA, Madhavan KK, Garden OJ, Parks RW. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2007;9:456-60.
23. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200:197-203.
24. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268-74.
25. Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest. 2012;30:571-6.
26. Porrata LF, Markovic SN. Is absolute lymphocyte count just another prognostic factor in cancer? SRX Med. 2010. doi:10. 3814/2010/812304.
27. Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40:793-808.
28. Tashiro T, Yamamori H, Takagi K, et al. Changes in immune function following surgery for esophageal carcinoma. Nutrition. 1999;15:760-6.
29. Corrigan M, Cahill RA, Redmond HP. The immunomodulatory effects of laparoscopic surgery. Surg Laparosc Endosc Percutan Tech. 2007;17:256-61.
30. Hegarty N, Dasgupta P. Immunological aspects of minimally invasive oncologic surgery. Curr Opin Urol. 2008;18:129-33.